SEOUL-SEMICONDUCTOR
7.12.2021 11:02:11 CET | Business Wire | Press release
From a research study 30% of dentists will suffer from visual reduction capabilities in the next 30 years. For FARO, the solutions are already here.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005033/en/
With the new dentist lamp Eva and the new ceiling panel Siderea equipped with SunLike LED technology, the historical and global market leader in the orthodontist equipment sector FARO wants to keep demonstrating their technological leadership and implement the latest technology available that can improve the healthcare of the users.
FARO has developed 2 new products with edge technology that will improve patients and doctors' lives, as new products include solar spectrum light that will help on concentration, relax and recovery activities as demonstrated by recent studies done by University of Basel and Harvard medical school.
The Eva lamp, completely developed, tested and manufactured in FARO headquarters in Ornago, near Milan, represents a technological revolution in the market. After many years of research the reflector is perfectly adapted to the new LED technology obtaining the perfect system combination that brings the best possible light and beam angle to the needed place.
The version Eva Sunlight uses the special SunLike LEDs from Seoul Semiconductor with a solar spectrum at any colour temperature of the light and produces the closest light to the real and natural Sunlight.
With an illumination of 50.000 lux the Eva luminaire can guide the professionals to see all the smallest details in their day to day operations and guarantee at the same time the maximum visual comfort for the patient and the dentist.
Talking about technical parameters the new luminaire is achieving the greatest quality of the light with a CRI of 97 and a TM30 of 100 that brings a perfect vision and colour reproduction of the oral cavities.
To get immediate feedback on the lighting level in use, you just have to take a look at the headlamp; it is also possible to manage all the functions from smartphones and tablets using the app FARO Tech that is available in all app stores.
Finally, Eva has an integrated camera (Eva Cam) which allows you to photograph and video record footage in FHD or even 4K to broadcast live or share images later on.
Siderea Sunlight is the natural complement of the Eva lamp. With the Theia Tech – the special lamp that talks with the intensive light – reducing the stress of the pre-operation for patients.
This combination of Siderea and Eva forms the FARO light system that has been developed to guarantee the ideal conditions for developing the dentists' work.
Siderea is the only dentist panel in the market with technology SunLike that mimics the effects of the natural light with a uniform, multidirectional and proportional light and it deletes all the shadows from traditional lamps. Reassuring the wellbeing and visual effects to operate in the perfect ambient.
“To improve people lives: this is our inspiration as entrepreneurs” explains Cristina Cesari, General Manager of FARO that today counts more than 700 customers, with products installed in more than 70 countries around the world.
“To reproduce the natural light is our main research driver and is a challenge of great fascination. Today we can bring the benefits of Seoul Semiconductor SunLike technology into the health medical area and improve all professional environments” added Cristina Cesari.
Oliver Schaefer, Executive Vice-president for Seoul Semiconductor Europe said “We are very honoured and proud to be part of the new FARO products with our latest LED technology SunLike that brings the Sun benefits to indoor spaces”.
About FARO
FARO is an historic Italian brand for lighting in the dental sector. FARO stands for high Italian quality, creativity and innovation. We provide products and “lighting systems” to improve the “light experience” because light is not only seen, but above all life and well-being. We are an enthusiastic company serving demanding and visionary customers. In FARO we provide cutting-edge technologies that are considered industry benchmarks, we work enthusiastically to go beyond the boundaries of research to enable the next generation of professional lighting.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike, WICOP, NanoDriver and nPola as examples.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom